Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Miller

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
Journal of Burn Care & Research : Official Publication of the American Burn Association|September 29, 2022
Burn Injury and Augmented Renal Clearance: A Case for Optimized Piperacillin-Tazobactam DosingSterling C Torian, Arek J Wiktor, Sara E Roper, et al.
Clinical Pharmacokinetics|December 21, 2021
Clinical Pharmacokinetics and Pharmacodynamics of DalbavancinKyle C Molina, Matthew A Miller, Scott W Mueller, et al.
Open Forum Infectious Diseases|July 15, 2021
Effectiveness of Bezlotoxumab for Prevention of Recurrent <i>Clostridioides difficile</i> Infection Among Transplant RecipientsTanner M Johnson, Amanda H Howard, Matthew A Miller, et al.
Oncotarget|January 19, 2017
Elimination of quiescent slow-cycling cells via reducing quiescence depth by natural compounds purified from Ganoderma lucidumJian Dai, Matthew A Miller, Nicholas J Everetts, et al.
Therapeutic Advances in Infectious Disease|January 22, 2024
Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort studyMartin Krsak, Sias Scherger, Matthew A Miller, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|September 8, 2018
A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infectionsMatthew A Miller, Douglas N Fish, Gerard R Barber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2021
Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for RecurrenceTanner M Johnson, Kyle C Molina, Amanda H Howard, et al.
BMC Infectious Diseases|January 24, 2024
Oritavancin as sequential therapy for Gram-positive bloodstream infectionsWilliams Monier Texidor, Matthew A Miller, Kyle C Molina, et al.
Expert Opinion on Pharmacotherapy|April 21, 2021
An overview of current and emerging antifungal pharmacotherapy for invasive fungal infectionsScott W Mueller, Sonya K Kedzior, Matthew A Miller, et al.
Open Forum Infectious Diseases|May 26, 2022
Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical SuccessTaylor Morrisette, Kyle C Molina, Beatriz Da Silva, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Journal of Burn Care & Research : Official Publication of the American Burn Association|September 29, 2022
Burn Injury and Augmented Renal Clearance: A Case for Optimized Piperacillin-Tazobactam DosingSterling C Torian, Arek J Wiktor, Sara E Roper, et al.
Clinical Pharmacokinetics|December 21, 2021
Clinical Pharmacokinetics and Pharmacodynamics of DalbavancinKyle C Molina, Matthew A Miller, Scott W Mueller, et al.
Open Forum Infectious Diseases|July 15, 2021
Effectiveness of Bezlotoxumab for Prevention of Recurrent <i>Clostridioides difficile</i> Infection Among Transplant RecipientsTanner M Johnson, Amanda H Howard, Matthew A Miller, et al.
Oncotarget|January 19, 2017
Elimination of quiescent slow-cycling cells via reducing quiescence depth by natural compounds purified from Ganoderma lucidumJian Dai, Matthew A Miller, Nicholas J Everetts, et al.
Therapeutic Advances in Infectious Disease|January 22, 2024
Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort studyMartin Krsak, Sias Scherger, Matthew A Miller, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|September 8, 2018
A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infectionsMatthew A Miller, Douglas N Fish, Gerard R Barber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2021
Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for RecurrenceTanner M Johnson, Kyle C Molina, Amanda H Howard, et al.
BMC Infectious Diseases|January 24, 2024
Oritavancin as sequential therapy for Gram-positive bloodstream infectionsWilliams Monier Texidor, Matthew A Miller, Kyle C Molina, et al.
Expert Opinion on Pharmacotherapy|April 21, 2021
An overview of current and emerging antifungal pharmacotherapy for invasive fungal infectionsScott W Mueller, Sonya K Kedzior, Matthew A Miller, et al.
Open Forum Infectious Diseases|May 26, 2022
Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical SuccessTaylor Morrisette, Kyle C Molina, Beatriz Da Silva, et al.
Pageof 7